DENTSPLY SIRONA Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DENTSPLY SIRONA Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | Mar 1, 2017 |
| FY2016 | Dec 31, 2015 | $0 | Mar 1, 2017 |
| FY2016 | Dec 31, 2014 | $0 | Mar 1, 2017 |
| FY2015 | Dec 31, 2013 | $0 | Feb 12, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.68B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.79B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.97B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $3.92B | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | $1.10B | Nov 7, 2022 |
| FY2021 | Sep 30, 2021 | $1.04B | Nov 7, 2022 |
| FY2021 | Jun 30, 2021 | $1.06B | Nov 7, 2022 |
| FY2021 | Mar 31, 2021 | $1.03B | Nov 7, 2022 |
| FY2021 | Dec 31, 2020 | $1.08B | Nov 7, 2022 |
| FY2021 | Sep 30, 2020 | $883.00M | Nov 7, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.09B | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $1.01B | Mar 15, 2018 |
| FY2017 | Jun 30, 2017 | $992.70M | Mar 15, 2018 |
| FY2017 | Mar 31, 2017 | $900.50M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $996.50M | Mar 15, 2018 |
| FY2017 | Sep 30, 2016 | $954.20M | Mar 15, 2018 |
| FY2017 | Jun 30, 2016 | $1.02B | Mar 15, 2018 |
| FY2017 | Mar 31, 2016 | $772.60M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $671.10M | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | $648.90M | Mar 1, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.84B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.96B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.09B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.13B | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | $604.00M | Nov 7, 2022 |
| FY2021 | Sep 30, 2021 | $569.00M | Nov 7, 2022 |
| FY2021 | Jun 30, 2021 | $595.00M | Nov 7, 2022 |
| FY2021 | Mar 31, 2021 | $579.00M | Nov 7, 2022 |
| FY2021 | Dec 31, 2020 | $567.00M | Nov 7, 2022 |
| FY2021 | Sep 30, 2020 | $432.00M | Nov 7, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($598.00M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($910.00M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($132.00M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($950.00M) | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | $119.00M | Nov 7, 2022 |
| FY2021 | Sep 30, 2021 | $84.00M | Nov 7, 2022 |
| FY2021 | Jun 30, 2021 | $96.00M | Nov 7, 2022 |
| FY2021 | Mar 31, 2021 | $112.00M | Nov 7, 2022 |
| FY2021 | Dec 31, 2020 | $105.00M | Nov 7, 2022 |
| FY2021 | Sep 30, 2020 | $47.00M | Nov 7, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($422.00M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($879.00M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($85.00M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($937.00M) | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | $172.00M | Nov 7, 2022 |
| FY2021 | Sep 30, 2021 | $132.00M | Nov 7, 2022 |
| FY2021 | Jun 30, 2021 | $154.00M | Nov 7, 2022 |
| FY2021 | Mar 31, 2021 | $150.00M | Nov 7, 2022 |
| FY2021 | Dec 31, 2020 | $141.00M | Nov 7, 2022 |
| FY2021 | Sep 30, 2020 | $72.00M | Nov 7, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $150.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $165.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $184.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $174.00M | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | $49.00M | Nov 7, 2022 |
| FY2021 | Sep 30, 2021 | $39.00M | Nov 7, 2022 |
| FY2021 | Jun 30, 2021 | $43.00M | Nov 7, 2022 |
| FY2021 | Mar 31, 2021 | $40.00M | Nov 7, 2022 |
| FY2021 | Dec 31, 2020 | $38.00M | Nov 7, 2022 |
| FY2021 | Sep 30, 2020 | $29.00M | Nov 7, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.61B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.61B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.59B | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | $377.00M | Nov 7, 2022 |
| FY2021 | Sep 30, 2021 | $395.00M | Nov 7, 2022 |
| FY2021 | Jun 30, 2021 | $393.00M | Nov 7, 2022 |
| FY2021 | Mar 31, 2021 | $386.00M | Nov 7, 2022 |
| FY2021 | Dec 31, 2020 | $373.00M | Nov 7, 2022 |
| FY2021 | Sep 30, 2020 | $313.00M | Nov 7, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $235.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $461.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $377.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $517.00M | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | $0 | Nov 7, 2022 |
| FY2021 | Sep 30, 2021 | $0 | Nov 7, 2022 |
| FY2021 | Jun 30, 2021 | $0 | Nov 7, 2022 |
| FY2021 | Mar 31, 2021 | $0 | Nov 7, 2022 |
| FY2022 | Dec 31, 2020 | $649.00M | Aug 7, 2023 |
| FY2021 | Dec 31, 2019 | $639.00M | Nov 7, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $149.00M | Aug 7, 2023 |
| FY2022 | Dec 31, 2021 | $142.00M | Aug 7, 2023 |
| FY2022 | Dec 31, 2020 | $87.00M | Aug 7, 2023 |
| FY2021 | Dec 31, 2019 | $123.00M | Nov 7, 2022 |
| FY2020 | Dec 31, 2018 | $183.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $144.30M | Mar 2, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.43B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.75B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $7.37B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $7.64B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $9.24B | Aug 7, 2023 |
| FY2021 | Dec 31, 2020 | $9.35B | Nov 7, 2022 |
| FY2020 | Dec 31, 2019 | $8.60B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $8.69B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $10.37B | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $11.56B | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.09B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.81B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $4.08B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.83B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.24B | Aug 7, 2023 |
| FY2021 | Dec 31, 2020 | $4.42B | Nov 7, 2022 |
| FY2020 | Dec 31, 2019 | $3.51B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $3.55B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $3.75B | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $3.43B | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.34B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.94B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.29B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.81B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $5.00B | Aug 7, 2023 |
| FY2021 | Dec 31, 2020 | $4.93B | Nov 7, 2022 |
| FY2020 | Dec 31, 2019 | $5.09B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $5.12B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $6.62B | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $8.11B | Mar 15, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.15B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.60B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.44B | Feb 27, 2025 |
| FY2023 | Jun 30, 2023 | $2.70B | Feb 29, 2024 |
| FY2023 | Mar 31, 2023 | $2.70B | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | $2.69B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.98B | Aug 7, 2023 |
| FY2022 | Dec 31, 2020 | $3.99B | Aug 7, 2023 |
| FY2021 | Dec 31, 2019 | $3.40B | Nov 7, 2022 |
| FY2020 | Dec 31, 2018 | $3.43B | Mar 1, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.56B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($835.00M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $205.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $456.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.51B | Aug 7, 2023 |
| FY2021 | Dec 31, 2020 | $1.20B | Nov 7, 2022 |
| FY2020 | Dec 31, 2019 | $1.40B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.23B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $2.32B | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $3.95B | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $326.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $272.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $334.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $365.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $339.00M | Aug 7, 2023 |
| FY2021 | Dec 31, 2020 | $438.00M | Nov 7, 2022 |
| FY2020 | Dec 31, 2019 | $405.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $309.60M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $320.60M | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $383.90M | Mar 8, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.28B | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | $1.75B | Feb 27, 2025 |
| FY2023 | Dec 31, 2023 | $1.91B | Feb 29, 2024 |
| FY2022 | Dec 31, 2022 | $1.87B | Aug 7, 2023 |
| FY2021 | Dec 31, 2021 | $1.92B | Nov 7, 2022 |
| FY2021 | Dec 31, 2020 | $2.28B | Nov 7, 2022 |
| FY2020 | Dec 31, 2019 | $1.44B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.58B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.63B | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $1.53B | Mar 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Nov 7, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Nov 7, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Nov 7, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Nov 7, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Nov 7, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Nov 7, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Nov 7, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Nov 7, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Nov 7, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Nov 7, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Nov 7, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Nov 7, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 199.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 198.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 207.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | 215.20M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | 217.40M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | 218.70M | Feb 29, 2024 |
| FY2020 | Dec 31, 2019 | 221.30M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 223.00M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 226.80M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | 230.10M | Mar 15, 2018 |